Montgomery County biopharma firm plans $500M stock offering while FDA reviews its NASH treatment application


A decision on the company's new drug application for its experimental NASH therapy is expected in the spring.

Previous Zenith Bank & Trust set to open in Phoenix after gaining federal approval
Next Elk Grove City Council schedules another meeting over Oak Rose Apartments